0
  • Business
  • Investing
  • Politics
  • Stocks
  • Latests news
The Investments Portal The Investments Portal
The Investments Portal The Investments Portal
The Investments Portal The Investments Portal
  • Business
  • Investing
  • Politics
  • Stocks
  • Latests news
The Investments Portal The Investments Portal
  • Business
  • Investing
  • Politics
  • Stocks
  • Latests news
The Investments Portal > Investing > RAD receives IND approval from US FDA for Betabart (RV-01)
Investing

RAD receives IND approval from US FDA for Betabart (RV-01)

July 28, 2025

Radiopharm Theranostics (RAD:AU) has announced RAD receives IND approval from US FDA for Betabart (RV-01)

Download the PDF here.

This post appeared first on investingnews.com

0 Shares
Share on Facebook Share on Twitter Share on Pinterest Share on Email
admin July 28, 2025
Previous Article The Real Drivers of This Market: AI, Semis & Robotics
Next Article S&P 500 Breaking Out Again: What This Means for Your Portfolio

You Might Also Enjoy

Top 5 Small-cap Pharma Stocks of 2025

August 16, 2025
READ MORE

Crypto Market Update: Bitcoin’s New High, Ethereum ETFs Outpace Bitcoin 5-to-1

August 16, 2025
READ MORE

Westport Files Preliminary Short Form Base Shelf Prospectus To Replace Expired Base Shelf Prospectus

August 16, 2025
READ MORE

Brunswick Exploration Consolidates Mirage Ownership

August 16, 2025
READ MORE

      Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


      By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.


      • About us
      • Privacy Policy
      • Terms & Conditions

      Copyright © 2024 TheInvestmentsPortal.com. All Rights Reserved.

      Our website uses cookies to improve your experience. Learn more about: Cookie Policy

      Accept